Why BGPT?
logo

Author Review — Track Authors' Data

Inspect an author's raw data, methods, and reproducibility across their publications.

Press Enter ↵ to find



    Fuel Your Discoveries




     Quick Explanation



    Data-integrity warning: the provided “OpenAlex Author Information” for query “Michael David” does not clearly identify a specific “Michael David” author; the top matched author shown is Jeroen J. Bax, and the provided “research data to utilize” contains many unrelated papers. I therefore cannot responsibly attribute scientific quality to “Michael David” from the evidence you supplied.
    If you share the target person’s ORCID, affiliation, or a list of their DOIs, I can do a precise, evidence-grounded author review.



     Long Explanation



    Author Review: “Michael David” — evidence mismatch & what can/can’t be concluded

    What you asked: critically review the scientific strength of the author “Michael David.”
    What your supplied evidence actually contains: (1) an “OpenAlex Author Information” block whose top match is Jeroen J. Bax (not “Michael David”), and (2) a large bundle of DOIs/paper-like extracted data that appears to cover multiple different research topics and different author teams, not clearly tied to “Michael David.”

    Therefore: any claim like “Michael David is X rigorous/novel” would be a non-evidenced attribution, which I will not do.

    1) Resolving the identity problem (known vs unknown)

    • Known from your OpenAlex block: the “top_author” shown is “Jeroen J. Bax” with a very large works_count and cited_by_count, and multiple guideline-related cardiology top works (e.g., ESC guidelines, atrial fibrillation/chronic coronary syndromes/valvular disease).
    • Unknown: which “Michael David” you mean (there may be many individuals with that name), and which of the included DOIs/paper excerpts belong to that person.
    • Implication for rigor scoring: I can score the evidence you provided (e.g., how strong the individual papers look), but I cannot validly score the author unless we can map the papers to “Michael David.”
    Action needed: an ORCID/affiliation/DOI list for “Michael David” (or confirmation that “Michael David” refers to one of the named authors in your OpenAlex block).

    2) Evidence strength of the included preclinical/biomedical papers (not attributed to a specific “Michael David”)

    Your dataset includes a JCI (doi:10.1172/JCI198843) glioblastoma + STING agonist + radiotherapy study with explicit in vivo model details and genetic perturbations, including host-vs-tumor STING effects and scRNA-seq/CellChat analyses. The extracted summary and reported methods include survival medians by treatment arm.

    Another included biomedical paper is the PFKFB2 cardiac metabolism–electrophysiology study ( .

    A structural-biology paper ( ) includes deposited PDB/EMDB identifiers in the provided excerpt.
    Core skeptic stance: paper-level “quality” is not the same as “author-level quality,” and strong methods in a multi-author paper do not automatically mean every coauthor personally produced the key analyses.

    3) Visualizing raw extracted survival medians (JCI STING+RT study)

    The following plot uses only the numeric median survival days values present in your extracted dataset for CT-2A and QPP8v arms. Missing medians ("undefined" in the extraction) are not plotted.
    Uncertainty note: the extraction labels several medians as undefined; this limits dose-combination inference from the provided numbers alone.

    4) What would strengthen an author-level review (and what to avoid)

    • Avoid: scoring “Michael David” based only on name matching without ORCID/affiliation/DOI mapping.
    • Prefer: coauthor position distributions, role-based contribution if available (e.g., corresponding author vs coauthor), and topic-consistent publication history.
    • Assess rigor: preregistration (if any), data/code availability, replicate experiments, proper controls, and whether conclusions are supported by the strongest endpoints (not just mechanistic surrogates).
    • Assess bias risks: publication bias, selective reporting, small n, model dependence (species translation), and correlation vs causation. Example: several provided biomedical studies explicitly mention translation/species limitations in the excerpt.

    Need the missing link: identify “Michael David”

    Provide ORCID (best) or at least 1–3 DOIs you know are by Michael David, and I’ll produce a defensible, citation-grounded author review.


    Feedback:   

    Updated: April 22, 2026

    BGPT Author Review



    Scientific Quality

    10%

    I cannot attribute the included papers or evidence to “Michael David” from the supplied material (identity mismatch/unclear mapping). Without verified authorship linkage (ORCID/affiliation/DOIs), any author-level scientific rigor score would be non-evidenced.



    Communication Quality

    30%

    Because the provided content is not actually a “Michael David” author work product (it’s mostly mixed paper extracts and an OpenAlex block for a different top author), I can’t fairly assess communication quality; at most, the supplied evidence is incomplete for that purpose.



    Author Novelty

    20%

    Novelty cannot be assigned to the named author without knowing which works are authored by “Michael David.” Some individual included papers appear novel at face value (e.g., cryoEM amyloid conversion), but that does not justify author-level novelty scoring.



    Scientific Rigor

    10%

    Author-level rigor cannot be assessed because the evidence does not establish that “Michael David” produced the included methods/analyses. Paper-level strengths vary, but attribution is missing.

     Top Data Sources ExportMCP



     Analysis Wizard



    Parses the extracted survival-median table into tidy arrays, filters missing medians, and generates publication-style summary plots for CT-2A and QPP8v arms using the provided numeric values.



     Hypothesis Graveyard



    A single-cell model where tumor STING status alone determines therapeutic response is less plausible given the extracted host-dependence pattern in the STING+RT study.


    A mechanism where NOS2 is the primary driver of efficacy is weakened if NOS2 knockout fails to abolish benefit (as suggested in the extracted STING+RT summary).

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Get Ahead With Science Insights

    Custom summaries of the latest cutting-edge research. Every Friday. No ads.


    My BGPT